Interní Med. 2016; 18(3): 134-136 | DOI: 10.36290/int.2016.031

Current problems of primary hyperparathyroidism in clinical practice

MUDr.Helena Šiprová1, prof.MUDr.Miroslav Souček, CSc.1, prof.MUDr.Květoslav Šipr, CSc.2
1 II. interní klinika LF MU a FN u sv. Anny v Brně
2 Ústav sociálního lékařství a veřejného zdravotnictví LF UP Olomouc

Primary hyperparathyroidism (PHPT) is the third most often endocrine disease worldwide and the number of cases is growing up

due to a frequent use of biochemical screening. Particularly number of asymptomatic and normocalcemic PHPT increases and

therapy results have improved significantly. It is necessary to treat also the asymptomatic patients, and in such a way reduce the

risk of major complications.

Keywords: parathyroid hormone, hyperparathyroidism, hypercalcemia, osteoporosis

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šiprová H, Souček M, Šipr K. Current problems of primary hyperparathyroidism in clinical practice. Interní Med. 2016;18(3):134-136. doi: 10.36290/int.2016.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Habib Z, Camacho P. Primary hyperparathyroidism: un update. Curr Opin Endocrinol Diabetes Obes 2010; 17(6): 554-560. Go to original source...
    2. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16: 33-39. Go to original source... Go to PubMed...
    3. Adámek S, Naňka O. Primární hyperparathyeróza: Diagnostika a terapie. Praha: Galén, 2006.
    4. Čáp J. Léčba primární hyperparatyreózy. Remedia 2010; 20: 96-98.
    5. Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism. In: Waas J, Stewart P. Oxford textbook of Endocrinology and Diabetes. 2nd edition. Oxford: Oxford University Press, 2011. Go to original source...
    6. Souček M. Vnitřní lékařství. Praha: Grada, 2011.
    7. Khan A, Bilezikian JP, Potts JT. Asymptomatic Primary Hyperparathyroidism: A Commentary on the Revisited Guidelines. Endocr Pract 2009; 15(5): 494-498. Go to original source... Go to PubMed...
    8. McDermott MT. Endocrine Secrets. 5 ed. Philadelphia: Mosby Elsevier, 2009.
    9. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3580-3594. Go to original source... Go to PubMed...
    10. Broulík P, Adámek S, Libánský P, Kubinyi J. Changes in the Pattern of Primary Hyperparathyroidism in Czech Republic. Prague Medical Report. 2015; 116(2): 112-121. Go to original source... Go to PubMed...
    11. Halenka M, Fryšák Z, Koranda P, Hluší A. Kombinace dosud asymptomatické primární hyperparatyreózy a papilokarcinomu štítné žlázy u pacienta s B-non-Hodgkinovým lymfomem. Interní med 2015; 17(1): 38-38.
    12. Bilezikian J, Khan A, Potts J. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94(2): 335-339. Go to original source... Go to PubMed...
    13. Silverber SJ, Walker MD, Bilezikian JP. Asymptomatic primary hyperparathyroidism. Clin Denzitom 2013; 16(1): 14-21. Go to original source... Go to PubMed...
    14. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 2014; 99(10): 3561-3569. Go to original source...
    15. Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: To treat or not to treat? Endocr Pract 2016; 22(3): 294-301. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.